EL7.AI
Stocks•23 July 2026•
1 min read

CVS Health Upgraded to Buy by Wall Street Zen Amid Analyst Optimism

Key Facts

1Wall Street Zen upgraded CVS Health (NYSE:CVS) to a 'Buy' rating from 'Hold'.
2The consensus among 21 analysts is a 'Moderate Buy' with a target price of $105.38.

In a move reflecting growing confidence in the healthcare sector, Wall Street Zen has upgraded CVS Health (NYSE:CVS) from 'Hold' to 'Buy'. This rating change follows Q1 earnings and revenue results that exceeded market expectations, leading to a more optimistic long-term outlook for the company. According to reports, the consensus among 21 analysts remains a 'Moderate Buy', signaling broad agreement on the stock's recovery potential.

Within the broader sector context, the average price target for the stock is now set at $105.38. Despite the positive upgrade, the shares experienced a 2.4% intraday decline, highlighting a disconnect between short-term price action and the improved fundamental outlook established after the company's strong quarterly performance.

CVS shares stood at $110.60 at close on July 21, 2026, having traded between a low of $107.30 and a high of $110.62 during that session. Investors should watch for upcoming US economic catalysts, such as the Consumer Price Index (CPI) release on July 17, which may impact broader market sentiment for healthcare and consumer-facing stocks.